Mission Family of Companies’ Espada Dermatology continues specialized therapeutic service line growth

SAN ANTONIO, July 26, 2017 -- For many years, San Antonio-based Mission Pharmacal Company (“Mission”) has manufactured and marketed highly specialized dermatology products. Utilizing only the finest ingredients, these products help ease patient suffering related to specific dermatologic conditions including acne, rosacea, seborrheic dermatitis, and other steroid responsive skin conditions. In 2016, the company acquired Glyderm® skin care products and formed Espada Dermatology, Inc. (“Espada”) to market the esthetic dermatology product line. A talented team of Mission dermatology experts and new leaders with their own extensive pharmaceutical experiences were brought together to lead Espada.The results have been so positive that Mission has shifted all products in its dermatology-related portfolio to Espada.

Trey Schutz, Espada Dermatology Vice President and General Manager

“We are working diligently, building on the strong foundation the Mission Dermatology team established as we continue to offer and develop high quality prescription products for a vast array of dermatological conditions,” says Espada Vice President and General Manager, Trey Schutz. “As the business has transitioned to Espada, we have been deliberate in our efforts to fulfill the ultimate objective of offering quality products that address new levels of patient care and achieve positive outcomes.”

Joining Schutz in leading Espada as Executive Director of the dermatology commercial team is David Kinnard who served in a similar role with Mission Dermatology. Together, Schutz and Kinnard oversee what now represents Mission’s (through Espada) most rapidly growing therapeutic area of focus.  The company offers a growing portfolio of both prescription and esthetic dermatology products through their specially trained dermatology sales force.

“Our intent has been to meld our collective experiences and long-lasting physician relationships to strengthen the overall program and the organization’s commitment to skin health innovation,” says Kinnard. “Going to events such as the American Academy of Dermatology (AAD) Summer Meeting (scheduled July 27-30 in New York City) provides a tremendous opportunity for us to spread the word about what we’re doing – what’s new and innovative – to help physicians, nurses, caregivers, and ultimately patients. It is an exciting time to be with the organization.”

About Espada Dermatology, Inc.

Espada Dermatology oversees a rapidly growing portfolio of both prescription and esthetic dermatology products. Formed to help healthcare providers address chronic and one-time dermatological conditions that may affect quality of life, Espada’s specially trained, highly qualified dermatology sales force has a reach that spans across the United States. Espada field representatives work closely with the healthcare community to provide product support and education to patients. For more information regarding Espada, visit missionpharmacal.com/familyofcompanies/espada.

Espada is a part of the Mission Family of Companies, a collection of wholly-owned subsidiaries created to diversify offerings and build forward-thinking partnerships with other pharmaceutical and biotech companies. Each company functions independently while their product and service offerings can be linked together to offer customizable solutions to a wide array of outside companies. Other Mission companies include: BioComp Pharma, Inc., a generic drug marketer; Alamo Pharma Services, Inc., a specialized contract sales organization; ProSolus, Inc., a transdermal drug developer and manufacturer;  as well as BexR Logistix, LLC and their subsidiary company, EPIC Fulfillment, Inc., the logistics and fulfillment arms of Mission. To learn more, please visit missionfamilyofcompanies.com.

# # #

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/430df72f-0462-44ab-9396-411bcbd6326f

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9d729fcc-3b33-40df-9b44-3daba79a0e5c

Drew Deeter
Espada Dermatology, Inc.
2153483890
[email protected]